Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report

Clin Lung Cancer. 2021 Nov;22(6):e878-e880. doi: 10.1016/j.cllc.2021.05.003. Epub 2021 May 21.
No abstract available

Keywords: BRAF fusion; MAPK pathway; lung adenocarcinoma; precision medicine; trametinib.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / pathology
  • Aged
  • Humans
  • Intracellular Signaling Peptides and Proteins / drug effects*
  • LIM Domain Proteins / drug effects*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Mitogen-Activated Protein Kinase Kinases / pharmacology*
  • Mitogen-Activated Protein Kinase Kinases / therapeutic use*
  • Mutation
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / drug effects*
  • Pyridones / pharmacology*
  • Pyridones / therapeutic use*
  • Pyrimidinones / pharmacology*
  • Pyrimidinones / therapeutic use*

Substances

  • Intracellular Signaling Peptides and Proteins
  • LIM Domain Proteins
  • LIMD1 protein, human
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Mitogen-Activated Protein Kinase Kinases